- Company
- U.S. executive order on drug price cuts raises hope
- by Kim, Jin-Gu May 14, 2025 06:10am
- U.S. President Donald Trump has signed an executive order to significantly reduce drug prices in the United States. This measure, which focuses on significantly reducing U.S. drug prices in line with overseas prices, is expected to have a positive effect on domestic biosimilars. However, some predict that the expected effects of this execu
- Product
- Patient organization proposes 6 policies as election pledges
- by Kang, Hye-Kyung May 14, 2025 06:10am
- A patient group has proposed six policies, including a “rapid reimbursement for new drugs and post-marketing adjustment system.” The Korea Alliance of Patients Organization submitted a 'Statement regarding Six Major Patient Policies' to political parties on the first day of the official campaign for the 21st presidential election on the
- Company
- How has Leqembi changed the clinical site in 6 months?
- by Moon, sung-ho May 14, 2025 06:09am
- The overall treatment system on-site has been changing with the introduction of Leqembi, a new dementia drug that was released 6 months ago in Korea. In response, experts are evaluating the therapeutic effects and side effects of Leqembi (lecanemab, Eisai Korea) while demanding improvements to the health insurance reimbursement system in vari
- Policy
- Reimb of comb cancer therapies w/o detailed criteria
- by Lee, Tak-Sun May 14, 2025 06:09am
- The reimbursement policy for combination cancer therapies, announced this month, has been implemented without detailed criteria, causing further confusion in medical practices. This was contributed by the Ministry of Health and Welfare (MOHW) and the Health Insurance Review and Assessment Service (HIRA), which had differing schedules for revi
- Company
- Vyloy quickly lands in general hospitals in Korea
- by Eo, Yun-Ho May 13, 2025 06:07am
- Vyloy, a targeted anticancer drug for gastric cancer, may be prescribed at general hospitals in Korea. According to industry sources, Vyloy (zolbetuximab), a Claudin 18.2-positive gastric cancer targeted therapy developed by Astellas Korea, is now available for prescription at the Big 5 tertiary hospitals in Korea, including Samsung Medic
- Company
- Mounjaro provides more weight loss than Wegovy
- by Eo, Yun-Ho May 13, 2025 06:06am
- Research results found Mounjaro brings more weight loss than its competitor Wegovy. On the 12th, Lilly announced the detailed results of the SURMOUNT-5 Phase IIIb open-label clinical trial directly comparing Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, and Wegovy (semaglutide), a GLP-1 receptor agonist. The study, which
- Policy
- CDRC to talk partial reimb details for comb cancer therapy
- by Lee, Tak-Sun May 13, 2025 06:06am
- An additional date has been set to discuss detailed criteria regarding partial reimbursement of combination cancer therapy, as announced this month. The Health Insurance Review and Assessment Service (HIRA) has decided to convene another Cancer Drug Review Committee (CDRC) meeting, which was not scheduled. According to industry sources
- Product
- Indiscriminate in-hospital prescriptions of Wegovy
- by Jung, Heung-Jun May 13, 2025 06:06am
- Criticism arose regarding the indiscriminate in-hospital prescriptions of Wegovy, which is currently allowed with an exception. According to the Korean Pharmaceutical Affairs Act, in-hospital prescription is allowed only when an 'injectable is injected.' However, it has been pointed out that Wegovy is being sold without a single act of inj
- Company
- U.S. pharmaceutical imports rise twofold amid tariff concern
- by Kim, Jin-Gu May 13, 2025 06:05am
- U.S. drug imports have nearly doubled in a year. This is believed to be the result of frontline pharmaceutical and biotech companies focusing on securing inventory in expectation of U.S. President Donald Trump's drug tariff imposition. According to Korea Biotechnology Industry Organization (KoreaBIO) on the 12th, the U.S. The United States C
- Company
- 'Retevmo' also seeks thyroid cancer reimbursement
- by Eo, Yun-Ho May 12, 2025 05:59am
- The RET-targeted cancer therapy 'Retevmo' seeks insurance reimbursement listing of its medullary thyroid cancer indication. According to sources, Lilly Korea recently submitted reimbursement applications simultaneously for the non&8211;small cell lung cancer indication and medullary thyroid cancer indication of the RET (REarranged during
